Hu Ye, Taylor-Harding Barbie, Raz Yael, Haro Marcela, Recouvreux Maria Sol, Taylan Enes, Lester Jenny, Millstein Joshua, Walts Ann E, Karlan Beth Y, Orsulic Sandra
Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Front Cell Dev Biol. 2020 Jul 17;8:647. doi: 10.3389/fcell.2020.00647. eCollection 2020.
Primary ovarian high-grade serous carcinoma (HGSC) has been classified into 4 molecular subtypes: Immunoreactive, Proliferative, Differentiated, and Mesenchymal (Mes), of which the Mes subtype (Mes-HGSC) is associated with the worst clinical outcomes. We propose that Mes-HGSC comprise clusters of cancer and associated stromal cells that detached from tumors in the upper abdomen/omentum and disseminated in the peritoneal cavity, including to the ovary. Using comparative analyses of multiple transcriptomic data sets, we provide the following evidence that the phenotype of Mes-HGSC matches the phenotype of tumors in the upper abdomen/omentum: (1) irrespective of the primary ovarian HGSC molecular subtype, matched upper abdominal/omental metastases were typically of the Mes subtype, (2) the Mes subtype was present at the ovarian site only in patients with concurrent upper abdominal/omental metastases and not in those with HGSC confined to the ovary, and (3) ovarian Mes-HGSC had an expression profile characteristic of stromal cells in the upper abdominal/omental metastases. We suggest that ovarian Mes-HGSC signifies advanced intraperitoneal tumor dissemination to the ovary rather than a subtype of primary ovarian HGSC. This is consistent with the presence of upper abdominal/omental disease, suboptimal debulking, and worst survival previously reported in patients with ovarian Mes-HGSC compared to other molecular subtypes.
原发性卵巢高级别浆液性癌(HGSC)已被分为4种分子亚型:免疫反应型、增殖型、分化型和间充质型(Mes),其中间充质型亚型(Mes-HGSC)与最差的临床结局相关。我们提出,Mes-HGSC由从上腹部/大网膜肿瘤脱离并播散至腹腔(包括卵巢)的癌和相关基质细胞簇组成。通过对多个转录组数据集的比较分析,我们提供了以下证据表明Mes-HGSC的表型与上腹部/大网膜肿瘤的表型相匹配:(1)无论原发性卵巢HGSC分子亚型如何,匹配的上腹部/大网膜转移瘤通常为Mes亚型;(2)Mes亚型仅在同时存在上腹部/大网膜转移的患者的卵巢部位出现,而在HGSC局限于卵巢的患者中未出现;(3)卵巢Mes-HGSC具有上腹部/大网膜转移瘤中基质细胞的特征性表达谱。我们认为卵巢Mes-HGSC表示腹腔内肿瘤晚期播散至卵巢,而非原发性卵巢HGSC的一种亚型。这与先前报道的卵巢Mes-HGSC患者与其他分子亚型相比存在上腹部/大网膜疾病、减瘤不充分和生存最差相一致。